title: The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment.
abstract: Vasopeptidase inhibitors (VPI) are a new promising class of drugs, that simultaneously inhibit Angiotensin - Converting Enzyme (ACE) and an enzyme Neutral Endopeptidase (NEP), that cleaves the natriuretic peptides. These drugs, such as omapatrilat, sampatrilat, fasidotrilat, by combined inhibition of ACE and degradation of natriuretic peptides and in turn by inhibiting the Renin - Angiotensin - Aldosterone system and potentiating the Natriuretic Peptide system and Kinin system should decrease the mortality rate in the group of patients with hypertension being not adequately controlled with ACE inhibitors. Thus, finding the new therapeutic strategy using drugs that act on the hormonal systems other than Renin - Angiotensin - Aldosterone system seems to be crucial. The aim of the study was to compare the molecular aspects of the conventional schemes that are being used in the antihypertension therapy to the new drugs from the vasopeptidase inhibitors group--with focusing on the natriuretic peptide system (NPS)--and, taking these considerations, making clues about therapeutical implications to reveal promising results in antihypertension treatment.
authors.affiliation: Department of Pathophysiology, Jagiellonian University, Medical College, Cracow, Poland. ania-maria@02.pl
authors.forename: Anna
authors.initials: A
authors.lastname: Machowska
authors.forename: Kajetan
authors.initials: K
authors.lastname: Juszczak
authors.forename: Paweł
authors.initials: P
authors.lastname: Novak
authors.forename: Piotr
authors.initials: P
authors.lastname: Thor
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D009320:Atrial Natriuretic Factor / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008698:Mesylates / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013564:Sympathetic Nervous System / Q000187:drug effects; D013841:Thiazepines / Q000627:therapeutic use; D014443:Tyrosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014655:Vascular Resistance / Q000187:drug effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D008698:Mesylates; D011480:Protease Inhibitors; D011725:Pyridines; D013841:Thiazepines; C097292:aladotrilat; C106266:omapatrilat; D014443:Tyrosine; D009320:Atrial Natriuretic Factor; D000409:Alanine; C111998:sampatrilat